Zacks Investment Research upgraded shares of CLEVELAND BIOLB (CBLI) from NEUTRAL to OUTPERFORM on March 25, 2013, with a target price of $2.20.
CLEVELAND BIOLABS, INC. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. The Company's proprietary technology platform is based on the ability to suppress or stimulate programmed cell death (apoptosis). CBLI's drugs can switch apoptosis on and off by affecting key regulators of cell response to stresses, such as radiation or ischemia. CBLI is pursuing three key areas of research: Biodefense for Acute Radiation Syndrome, Cancer Treatment, and Tissue Protection.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on CLEVELAND BIOLB (CBLI),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment